São Paulo - Delayed Quote • BRL
BeiGene, Ltd. (B1GN34.SA)
At close: September 13 at 11:46 AM GMT-3
All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
NICE recommends BeiGene’s MZL tablet for NHS use
Zanubrutinib can be administered as once or twice-daily capsules at home.
Pharmaceutical Technology • last month -
-
Performance Overview
Trailing total returns as of 9/13/2024, which may include dividends or other distributions. Benchmark is HANG SENG INDEX
Return | B1GN34.SA | HANG SENG INDEX |
---|---|---|
YTD | +28.99% | +1.89% |
1-Year | +3.53% | -3.64% |
3-Year | -39.60% | -33.72% |